Thyroid cancer, BRAF-mutated
If you are interested in this role, please contact us at [email protected].
Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
Differentiated thyroid cancer, all lines of therapy
|Study||Years of enrollment||Evidence|
|Brose et al. 2016 (NO25530)||2011-2013||Phase 2|
Note: this study was in patients with papillary thyroid cancer, only.
- Vemurafenib (Zelboraf) 960 mg PO twice per day
- NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01286753
Anaplastic thyroid cancer, all lines of therapy
Dabrafenib & Trametinib
|Study||Years of enrollment||Evidence||Efficacy|
|Subbiah et al. 2017 (ROAR)||2014-2016||Phase 2, <20 pts in subgroup (RT)||ORR: 63% (95% CI, 35-85)|
Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.
- ROAR: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02034110
- Update: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022 Apr;33(4):406-415. Epub 2022 Jan 10. link to original article PubMed